

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)


PCT

(10) International Publication Number
WO 2004/043238 A2

- (51) International Patent Classification⁷: **A61B** MI 4804 (US). CHRISTNER, Robert [US/US]; 2262 Parkwood Avenue, Toledo, OH 43620 (US).
- (21) International Application Number: PCT/US2003/036120
- (22) International Filing Date: 13 November 2003 (13.11.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/426,096 14 November 2002 (14.11.2002) US
- (71) Applicant (for all designated States except US): CIPHER-GEN BIOSYSTEMS, INC. [US/US]; 6611 Dumbarton Circle, Fremont, CA 94555 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BUHIMSCHI, Irina, A. [US/US]; 2728 Alisop Place, Apt. 309, Troy,
- (74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Washington Harbour, Suite 500, 3000 "K" Street, N.W., Washington, DC 20007-5101 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: BIOMARKERS FOR INTRO-AMNIOTIC INFLAMMATION



(57) Abstract: Biomarkers have been discovered that are capable of identifying intra-amniotic inflammation. A single biomarker or combination of biomarkers can be used to qualify the risk of preterm delivery in a patient, provided that at least one of the biomarkers is a calgranulin, preferably calgranulin A or C. The result is a rapid and reliable proteomic approach to identifying intra-amniotic inflammation. In particular, the concentrations of the biomarkers correlate with the magnitude of intra-amniotic inflammation and, hence, of preterm delivery.

WO 2004/043238 A2

WO 2004/043238 A2



Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.